1. Academic Validation
  2. Development and Characterization of a Fluorescent Ligand for Leukotriene B4 Receptor 2 in Cells and Tissues

Development and Characterization of a Fluorescent Ligand for Leukotriene B4 Receptor 2 in Cells and Tissues

  • J Med Chem. 2022 Feb 10;65(3):2023-2034. doi: 10.1021/acs.jmedchem.1c01589.
Jan Heering 1 Victor Hernandez-Olmos 1 Niklas Ildefeld 2 Ting Liu 2 Anja Kaiser 2 Zumer Naeem 3 Timo Frömel 3 Ingrid Fleming 3 Dieter Steinhilber 1 2 Ewgenij Proschak 1 2
Affiliations

Affiliations

  • 1 Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, D-60596 Frankfurt, Germany.
  • 2 Institute of Pharmaceutical Chemistry, Goethe-University, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany.
  • 3 Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, D-60596 Frankfurt am Main, Germany.
Abstract

The leukotriene B4 receptor 2 (BLT2) is a G-protein coupled receptor activated by 12(S)-hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT), which has been proposed as a promising therapeutic target for diabetic wound healing and gastrointestinal lesions. In this study, the rational design of a fluorescent probe based on the synthetic BLT2 agonist CAY10583 is described. The synthesis of several derivatives of CAY10583 coupled to fluorescein resulted in a traceable ligand suitable for different fluorescence-based techniques. An HTRF-based displacement assay (Tag-lite) on stably transfected CHO-K1 cells was developed to characterize binding properties of diverse BLT2 ligands. Highly specific binding to the BLT2 receptor was demonstrated in staining experiments on mouse skin tissue, and specific modulation of BLT2-induced cAMP signaling provided further evidence for receptor binding and ligand functionality. In conclusion, the fluorescent ligands developed in this study are suitable to investigate the pharmacology of BLT2 receptor ligands in a variety of assay systems.

Figures
Products